{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T12:01:35Z","timestamp":1761393695516,"version":"3.44.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1016\/j.metabol.2008.02.014","type":"journal-article","created":{"date-parts":[[2008,6,14]],"date-time":"2008-06-14T04:23:24Z","timestamp":1213417404000},"page":"973-979","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Rosuvastatin selectively stimulates apolipoprotein A-I but not apolipoprotein A-II synthesis in Hep G2 cells"],"prefix":"10.1016","volume":"57","author":[{"given":"Shucun","family":"Qin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Koga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shobha H.","family":"Ganji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vaijinath S.","family":"Kamanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moti L.","family":"Kashyap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2008.02.014_bib1","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1177\/009127000204200902","article-title":"A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin","volume":"42","author":"White","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.metabol.2008.02.014_bib2","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1586\/14779072.1.4.495","article-title":"Rosuvastatin: a new inhibitor of HMG-CoA reductase for the treatment of dyslipidemia","volume":"1","author":"Rosenson","year":"2003","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.metabol.2008.02.014_bib3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2165\/00129784-200404020-00005","article-title":"Rosuvastatin: a review of its use in the management of dyslipidemia","volume":"4","author":"Scott","year":"2004","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.metabol.2008.02.014_bib4","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.clinthera.2004.09.006","article-title":"Statin therapies for elevated lipid levels compared across doses to rosuvastatin study group","volume":"26","author":"Jones","year":"2004","journal-title":"Clin Ther"},{"key":"10.1016\/j.metabol.2008.02.014_bib5","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000070669","article-title":"Rosuvastatin, a highly effective new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor: a review of clinical trial data at 10-40 mg doses in dyslipidemic patients","volume":"99","author":"Schuster","year":"2003","journal-title":"Cardiology"},{"key":"10.1016\/j.metabol.2008.02.014_bib6","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.clinthera.2004.09.005","article-title":"Rosuvastatin in the management of hyperlipidemia","volume":"26","author":"Cheng","year":"2004","journal-title":"Clin Ther"},{"key":"10.1016\/j.metabol.2008.02.014_bib7","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/S0002-9149(03)00318-7","article-title":"Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels","volume":"91","author":"Capuzzi","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.metabol.2008.02.014_bib8","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0002-9149(02)02994-6","article-title":"Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease","volume":"91","author":"Schneck","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.metabol.2008.02.014_bib9","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.2165\/00003495-200464110-00003","article-title":"Medical lipid-regulating therapy: current evidence, ongoing trials and future developments","volume":"64","author":"Evans","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.metabol.2008.02.014_bib10","doi-asserted-by":"crossref","first-page":"23K","DOI":"10.1016\/S0002-9149(03)00779-3","article-title":"Benefit-risk assessment of rosuvastatin 10 to 40 milligrams","volume":"92","author":"Brewer","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.metabol.2008.02.014_bib11","series-title":"Preventive cardiology","first-page":"183","article-title":"Dyslipidemia","author":"Wong","year":"2004"},{"key":"10.1016\/j.metabol.2008.02.014_bib12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0002-9149(93)90708-K","volume":"71","author":"Rubins","year":"1993","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.metabol.2008.02.014_bib13","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0022-2275(20)39898-9","article-title":"Molecular physiology of reverse cholesterol transport","volume":"36","author":"Fielding","year":"1995","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2008.02.014_bib14","doi-asserted-by":"crossref","first-page":"56H","DOI":"10.1016\/0002-9149(89)90118-5","article-title":"Basic considerations in the reversal of atherosclerosis: significance of high density lipoproteins in stimulating reverse cholesterol transport","volume":"63","author":"Kashyap","year":"1989","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.metabol.2008.02.014_bib15","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0006-291X(87)90451-7","article-title":"Cholesterol efflux from cultured adipose cells is mediated by LP A-I particles but not by LP A-I:A-II particles","volume":"142","author":"Barbaras","year":"1987","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.metabol.2008.02.014_bib16","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1161\/hq1001.096624","article-title":"Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol","volume":"21","author":"Sakai","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2008.02.014_bib17","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0005-2760(98)00082-4","article-title":"Selective uptake of cholesteryl esters from high-density lipoprotein\u2013derived LPA-I and LPA-I:A-II particles by hepatic cells in culture","volume":"1393","author":"Rinninger","year":"1998","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.metabol.2008.02.014_bib18","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1126\/science.8332912","article-title":"Atherosclerosis in transgenic mice overexpressing apolipoprotein AII","volume":"26","author":"Warden","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.metabol.2008.02.014_bib19","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1161\/01.ATV.20.11.2453","article-title":"Decreased susceptibility to diet-induced atherosclerosis in human apolipoprotein A-II transgenic mice","volume":"20","author":"Tailleux","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2008.02.014_bib20","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1161\/CIRCULATIONAHA.107.704031","article-title":"Apolipoprotein AII is inversely associated with risk of future coronary artery disease","volume":"116","author":"Birjmohun","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2008.02.014_bib21","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1161\/01.ATV.17.10.2020","article-title":"Niacin decreases removal of high density lipoprotein AI but not cholesterol ester by Hep G2 cells","volume":"17","author":"Jin","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2008.02.014_bib22","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1161\/01.ATV.18.6.999","article-title":"Estradiol stimulates apolipoprotein AI\u2013 but not AII\u2013containing particle synthesis and secretion by stimulating mRNA transcription rate in Hep G2 cells","volume":"18","author":"Jin","year":"1998","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2008.02.014_bib23","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1161\/01.ATV.16.8.1052","article-title":"Gemfibrozil stimulates apolipoprotein AI synthesis and secretion by stabilization of mRNA transcripts in human hepatoblastoma cell line","volume":"16","author":"Jin","year":"1996","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2008.02.014_bib24","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/353265a0","article-title":"Inhibition of early atherogenesis in transgenic mice by human apolipoprotein A-I","volume":"353","author":"Rubin","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.metabol.2008.02.014_bib25","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/365762a0","article-title":"Protein composition determines the anti-atherogenic properties of HDL in transgenic mice","volume":"365","author":"Schultz","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.metabol.2008.02.014_bib26","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0021-9150(87)90091-8","article-title":"Apolipoprotein A-I\u2013containing lipoproteins in coronary artery disease","volume":"68","author":"Puchois","year":"1987","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.metabol.2008.02.014_bib27","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/01.ATV.13.11.1640","article-title":"Parental history of early myocardial infarction is associated with decreased levels of lipoprotein particles A-I in adolescents","volume":"13","author":"Amouyel","year":"1993","journal-title":"Arterioscler Thromb"},{"key":"10.1016\/j.metabol.2008.02.014_bib28","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/clinchem\/36.8.1431","article-title":"Differential electroimmunoassay of human LP-AI lipoprotein particles on ready-to-use plates","volume":"36","author":"Parra","year":"1990","journal-title":"Clin Chem"},{"key":"10.1016\/j.metabol.2008.02.014_bib29","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/01.ATV.16.3.431","article-title":"Oral estrogen replacement therapy in postmenopausal women selectively raises levels and production rates of lipoprotein A-I and lowers hepatic lipase activity without lowering the fractional catabolic rate","volume":"16","author":"Brinton","year":"1996","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2008.02.014_bib30","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1172\/JCI10852","article-title":"Statin-induced inhibition of the Rho-signaling pathway activities PPARa and induces HDL apoA-I","volume":"107","author":"Martin","year":"2001","journal-title":"J Clin Invest"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049508000851?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049508000851?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T03:27:40Z","timestamp":1758425260000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049508000851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["S0026049508000851"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2008.02.014","relation":{},"ISSN":["0026-0495"],"issn-type":[{"type":"print","value":"0026-0495"}],"subject":[],"published":{"date-parts":[[2008,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rosuvastatin selectively stimulates apolipoprotein A-I but not apolipoprotein A-II synthesis in Hep G2 cells","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2008.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}